| |
Plasma Interferon-γ-Inducible Protein 10 (IP-10) and Response to
Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype
1-Infected Patients With and Without Cirrhosis - Abbvie Analysis
|
| |
| |
" In the era of interferon (IFN)-based therapies for hepatitis C virus (HCV) infection, elevated interferon-γ-inducible protein 10 (IP-10; CXCL10) levels predicted poor virologic response, particularly when associated with an unfavorable IL28B non-CC genotype1,2......[this study found] SVR rates were similar irrespective of elevated baseline IP-10 levels with prospective confounding factors of IL28B genotype, HCV sub genotype, and race (Figure 3)"
Reported by Jules Levin
DDW 2015
Digestive Disease Week, May 17-19, 2015, Washington, DC
Jordan J Feld1, Gregory J Dore2, David Wyles3, Eric Lawitz4, Andrew H Talal5,6, Greg Ball7, Emily O Dumas7, Ira M Jacobson5
1Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 2Kirby Insti tute, UNSW Australia, and St. Vincent's Hospital, Sydney, Australia; 3University of California San Diego, La Jolla, California, United States; 4The Texas Liver Insti tute, University of Texas Health Science Center, San Antonio, Texas, United States;
5Weill Cornell Medical College, New York, New York, United States; 6University at Buffalo, Buffalo, New York, United States; 7AbbVie Inc., North Chicago, Illinois, United States; 8Icahn School of Medicine at Mount Sinai, New York, New York, United States
|
|
| |
| |
|
|
|
